

Systemtherapien beim metastasierten nicht-klarzelligen Nierenzellkarzinom

Jens Bedke

Literatur

1. Hora M et al. European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View. *Eur Urol* 2023; 83(2): 97–100
2. Ljungberg B et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol* 2022; 82(4): 399–410
3. Gore ME et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. *Lancet Oncol* 2009; 10(8): 757–63
4. Hudes G et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007; 356(22): 2271–81
5. Koh Y et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. *Ann Oncol* 2013; 24(4): 1026–31
6. Pal SK et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. *Lancet* 2021; 397(10275): 695–703
7. McDermott DF et al. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. *J Clin Oncol* 2021; 39(9): 1029–39
8. Lee CH et al. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. *J Clin Oncol* 2022; 40(21): 2333–41
9. Lee CH et al., KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). *Journal of Clinical Oncology* 2021; 39(15_suppl): TPS4595-TPS4595
10. Tykodi SS et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. *J Immunother Cancer* 2022; 10(2)
11. Ahrens M et al. A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST). *Journal of Clinical Oncology* 2020; 38(15_suppl): TPS5103-TPS5103
12. Choueiri TK et al. SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC). *Journal of Clinical Oncology* 2022; 40(16_suppl): TPS4601-TPS4601